Disrupting a channel to regulate depression
Major depressive disorder, or MDD, affects 17% of adults in the U.S. Even with treatment, many patients experience refractory symptoms and may experiment with multiple medications to find a pharmacotherapy that works. Even effective therapies can be hindered by side effects such as changes in weight and sleeping habits.
Nearly all existing antidepressants target neurotransmitters such as serotonin. However, a recent breakthrough in a Vanderbilt University Medical Center lab regulates protein–protein interactions in the brain and could offer one new path to treatment.

Dane Chetkovich’s lab has long been interested in MDD and how it can be treated by targeting ion channels in the hippocampus. Ye Han, a research associate professor in the lab, and colleagues recently published a paper in the Journal of Biological Chemistry announcing the discovery of a small molecule capable of disrupting a key pathway in the brain linked to the disorder.
Researchers in the lab had found previously that hyperpolarization-activated, cyclic nucleotide-gated — or HCN — channels are elevated in people with MDD as well as in animals that have been genetically altered to experience chronic social stress. This was an important breakthrough in understanding the disorder and provided a molecular target for developing new therapies. However, HCN channels are present in both the heart and the brain, and compounds designed to limit HCN channel function can produce heart arrhythmias.
“We know HCN is the therapeutic target, but we needed a way to exclusively target these channels in the brain,” Han said. “We need to be able to target HCN indirectly.”
As far back as 2010, Han and Chetkovich were studying a supporting subunit of HCN channels that can regulate HCN channel activity specifically in the brain. This subunit is called tetratricopeptide-repeat containing, Rab8b-interacting protein, or TRIP8b. It binds to HCN pore-forming subunits to regulate HCN channel function and subcellular distribution.
TRIP8b turned out to be the key to unlocking HCN channel regulation in MDD. When TRIP8b is knocked out in the brains of animals, HCN channel expression decreases.
Han took this discovery a step further in the work described in this recent JBC paper, using a high-throughput virtual screen to identify a small molecule, NUCC-0200590, that can disrupt the HCN–TRIP8b interaction both in the test tube and in animals.
The lab now is working on developing this small molecule into a drug that could be used in the clinic. This means screening to test analogs and concentrations for their effect on the HCN–TRIP8b interaction to improve potency and stability, with the long-term goal of bringing it to a clinical trial.
“This novel approach takes advantage of a specific mechanism found only in the brain and has the potential to improve how MDD is treated,” Han said.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

CRISPR epigenome editor offers potential gene therapies
Scientists from the University of California, Berkeley, created a system to modify the methylation patterns in neurons. They presented their findings at ASBMB 2025.

Finding a symphony among complex molecules
MOSAIC scholar Stanna Dorn uses total synthesis to recreate rare bacterial natural products with potential therapeutic applications.

E-cigarettes drive irreversible lung damage via free radicals
E-cigarettes are often thought to be safer because they lack many of the carcinogens found in tobacco cigarettes. However, scientists recently found that exposure to e-cigarette vapor can cause severe, irreversible lung damage.

Using DNA barcodes to capture local biodiversity
Undergraduate at the University of California, Santa Barbara, leads citizen science initiative to engage the public in DNA barcoding to catalog local biodiversity, fostering community involvement in science.

Targeting Toxoplasma parasites and their protein accomplices
Researchers identify that a Toxoplasma gondii enzyme drives parasite's survival. Read more about this recent study from the Journal of Lipid Research.

Scavenger protein receptor aids the transport of lipoproteins
Scientists elucidated how two major splice variants of scavenger receptors affect cellular localization in endothelial cells. Read more about this recent study from the Journal of Lipid Research.